Author: Mazalovska, Milena; Kouokam, J. Calvin
Title: Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections Document date: 2018_5_8
ID: 0spmy8vn_49
Snippet: Lectins are highly potent in neutralizing a very broad range of HIV strains and other enveloped viruses, with potential activity against multiple pathogenic prokaryotic and eukaryotic organisms that further complicate the HIV/AIDS problem. Therefore, these molecules deserve in-depth assessment for their inclusion in current efforts to end HIV infection. It should be noted that some lectins possess cytotoxicity and mitogenicity, which could potent.....
Document: Lectins are highly potent in neutralizing a very broad range of HIV strains and other enveloped viruses, with potential activity against multiple pathogenic prokaryotic and eukaryotic organisms that further complicate the HIV/AIDS problem. Therefore, these molecules deserve in-depth assessment for their inclusion in current efforts to end HIV infection. It should be noted that some lectins possess cytotoxicity and mitogenicity, which could potentially lead to severe adverse effects if used in humans. Meanwhile, most lectins are not monospecific and actually recognize a handful of different sugar types. Those recognizing glycans found on the surface of normal human cells have the potential to elicit off-target toxicity. However, comprehensive studies by our team and others have demonstrated the safety of GRFT. While still in preclinical development, lectins have shown tremendous potential to inhibit HIV and other pathogens and could be used to prevent multiple infections and/or improve the overall health status of HIV infected individuals.
Search related documents:
Co phrase search for related documents- adverse effect and health status: 1, 2, 3, 4, 5, 6, 7
- adverse effect and HIV infection: 1, 2, 3, 4
- adverse effect and HIV strain: 1
- adverse effect and human cell: 1, 2
- adverse effect and potential activity: 1, 2, 3
- adverse effect and preclinical development: 1, 2
- adverse effect and severe adverse effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- broad range and comprehensive study: 1, 2, 3
- broad range and enveloped virus: 1, 2, 3, 4, 5, 6, 7, 8
- broad range and health status: 1, 2, 3, 4, 5, 6
- broad range and HIV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- broad range and HIV strain: 1
- broad range and human cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- broad range and multiple infection: 1, 2, 3, 4
- broad range and potential activity: 1, 2, 3, 4, 5, 6
- broad range and target toxicity: 1
- broad range and tremendous potential: 1
- comprehensive study and enveloped virus: 1
- comprehensive study and GRFT safety: 1
Co phrase search for related documents, hyperlinks ordered by date